Want to see RNA full AI Analyst Report?

Atrium Therapeutics, Inc. (RNA) Price & Analysis

23 Followers

RNA Stock Chart & Stats

$13.64

-$0.39(-1.27%)

At close: Jan 08 4:00 PM EST

$13.64

-$0.39(-1.27%)

Day’s Range― - ―

52-Week Range$7.49 - $16.77

Previous CloseN/A

Volume185.29K

Average Volume (3M)388.18K

Market Cap

$169.52M

Enterprise Value-$32.45M

Total Cash (Recent Filing)$264.21M

Total Debt (Recent Filing)$1.68M

Price to Earnings (P/E)―

Beta1.53

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding22,276,028

10 Day Avg. Volume254,573

30 Day Avg. Volume388,181

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)1.22

Price to Sales (P/S)13.56

P/FCF Ratio-5.93

Enterprise Value/Market Cap-0.19

Enterprise Value/Revenue-0.90

Enterprise Value/Gross Profit-0.91

Enterprise Value/Ebitda0.12

Forecast

1Y Price Target

$25.00

Price Target Upside83.28% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageVery low leverage gives the company greater financial flexibility than a highly indebted business and limits near-term refinancing pressure. This can help management direct available resources toward operations while reducing the balance-sheet burden during continued development and losses.

High Gross MarginExceptionally high reported gross margins indicate that revenue, where generated, carries substantial gross profit before operating expenses. If revenue expands, this structure could provide operating leverage, although current losses show that scale has not yet covered the company’s investment base.

Improving LossesImprovement from the extreme losses recorded in 2024 suggests some progress in the company’s financial trajectory, even though it remains deeply unprofitable. Continued improvement would reduce the pace at which resources are consumed and could strengthen future funding flexibility.

Bears Say

Persistent Cash BurnPersistent operating and free-cash-flow deficits indicate that the business is consuming substantial cash rather than funding itself. The sharp decline in free cash flow and reliance on external funding can constrain investment choices and increase financing needs over the coming quarters.

Small, Volatile RevenueA small and volatile revenue base provides limited support for the company’s large operating cost structure and makes financial results difficult to scale predictably. The recent decline reinforces the challenge of converting reported activity into a durable growth trajectory.

Contracting Balance SheetMaterial contraction in equity and total assets indicates that the company’s financial base has weakened over time, consistent with pressure from ongoing losses and cash use. Combined with deeply negative return on equity, this reduces resilience and limits internally funded growth.

Atrium Therapeutics, Inc. News

Atrium Therapeutics announces $50M private placement

Atrium Therapeutics (RNA) announced that it has entered into a securities purchase agreement with a group of institutional...

13d ago

RNA

Atrium Therapeutics earns $15M milestone payment from Bristol Myers

Atrium Therapeutics (RNA) announced it has earned another $15M milestone payment from Bristol Myers Squibb (BMY) based on...

2M ago

BMY

RNA

Atrium Therapeutics reports Q2 EPS ($1.18) vs (75c) last year

Reports Q2 revenue $3M vs $3.85M last year. “Our team continues to execute well, achieving FDA clearance of...

2M ago

RNA

Zillow downgraded, Global Payments upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

3M ago

Atrium Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Atrium Therapeutics (RNA) with a Buy rating and $25 price target The company...

3M ago

RNA

Atrium Therapeutics announces FDA clearance of ATR 1072 IND application

Atrium Therapeutics (RNA) announced that the FDA has cleared its investigational new drug, or IND, application allowing the...

3M ago

RNA

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target Atrium’s RNA...

4M ago

RNA

Atrium Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Atrium Therapeutics (RNA) with an Overweight rating and $25 price target Published first...

4M ago

RNA

Leerink starts ‘interesting preclinical-stage opportunity’ Atrium at Outperform

Leerink initiated coverage of Atrium Therapeutics (RNA) with an Outperform rating and $25 price target calling the company...

5M ago

RNA

Atrium Therapeutics initiated with an Outperform at Leerink

Leerink initiated coverage of Atrium Therapeutics (RNA) with an Outperform rating and $25 price target Published first on...

5M ago

RNA

RNA Earnings this Week: How Will it Perform?

Avidity Biosciences Inc (RNA) is scheduled to report 4th quarter earnings on 03/03/2026. Regarding Q4 estimates, Wall Street...

8M ago

RNA

Morning News Wrap-Up 2/27/26: Today’s Biggest Stock Market Stories!

Traders will find the best stock market stories to read on Friday in our daily wrap-up. ...

8M ago

DIA

RNA

Avidity Biosciences Completes Merger and Plans Nasdaq Delisting

Avidity Biosciences ( ($RNA) ) has issued an update. Following the closing of a previously agreed merger, Avidity...

8M ago

RNA

Why Is Avidity Biosciences Stock (RNA) Down Today?

Avidity Biosciences stock appeared to take a beating on Friday following a deal with Novartis. ...

8M ago

NVS

RNA

RNA FAQ

What was Atrium Therapeutics, Inc.’s price range in the past 12 months?

Atrium Therapeutics, Inc. lowest stock price was $7.49 and its highest was $16.77 in the past 12 months.

What is Atrium Therapeutics, Inc.’s market cap?

Atrium Therapeutics, Inc.’s market cap is $169.52M.

When is Atrium Therapeutics, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Atrium Therapeutics, Inc.’s earnings last quarter?

Currently, no data Available

Is Atrium Therapeutics, Inc. overvalued?

According to Wall Street analysts Atrium Therapeutics, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Atrium Therapeutics, Inc. pay dividends?

Atrium Therapeutics, Inc. does not currently pay dividends.

What is Atrium Therapeutics, Inc.’s EPS estimate?

Atrium Therapeutics, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Atrium Therapeutics, Inc. have?

Atrium Therapeutics, Inc. has 22,276,028 shares outstanding.

What happened to Atrium Therapeutics, Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Atrium Therapeutics, Inc.?

Currently, no hedge funds are holding shares in RNA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Atrium Therapeutics, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-42.90%

Trailing 12-Months

Asset Growth

―

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.

Atrium Therapeutics, Inc. (RNA) Earnings & Revenues

Historic Earnings Reports

RNA Stock 12 Month Forecast

Average Price Target

$25.00

▲(83.28% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","26":"$26","11.75":"$11.75","16.5":"$16.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,11.75,16.5,21.25,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.14,9.436923076923078,10.733846153846155,12.03076923076923,13.327692307692308,14.624615384615385,15.92153846153846,17.21846153846154,18.515384615384615,19.81230769230769,21.10923076923077,22.406153846153845,23.70307692307692,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.14,9.436923076923078,10.733846153846155,12.03076923076923,13.327692307692308,14.624615384615385,15.92153846153846,17.21846153846154,18.515384615384615,19.81230769230769,21.10923076923077,22.406153846153845,23.70307692307692,{"y":25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.14,9.436923076923078,10.733846153846155,12.03076923076923,13.327692307692308,14.624615384615385,15.92153846153846,17.21846153846154,18.515384615384615,19.81230769230769,21.10923076923077,22.406153846153845,23.70307692307692,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.75,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.75,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.91,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.47,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.43,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.3,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.35,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.77,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.14,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >